GlaxoSmithKline’s Nucala targets rival AstraZeneca with FDA nod for rare white blood cell disease
GlaxoSmithKline’s immunology leader Nucala has been locked in a yearslong struggle with AstraZeneca’s Fasenra for dominance in rare eosinophilic asthma. With a new rare disease...